Zimmer Biomet Holdings Inc (ZBH) CEO Bryan C. Hanson Buys 410 Shares
Zimmer Biomet Holdings Inc (NYSE:ZBH) CEO Bryan C. Hanson bought 410 shares of the firm’s stock in a transaction that occurred on Friday, August 31st. The shares were purchased at an average cost of $123.03 per share, for a total transaction of $50,442.30. Following the purchase, the chief executive officer now owns 25,487 shares in the company, valued at approximately $3,135,665.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
ZBH stock opened at $121.97 on Wednesday. The company has a current ratio of 2.41, a quick ratio of 1.25 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $25.16 billion, a price-to-earnings ratio of 15.19, a P/E/G ratio of 2.25 and a beta of 1.09. Zimmer Biomet Holdings Inc has a 1 year low of $104.28 and a 1 year high of $129.34.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Friday, July 27th. The medical equipment provider reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.88 by $0.04. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.99 billion. Zimmer Biomet had a return on equity of 13.53% and a net margin of 21.67%. Zimmer Biomet’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.08 EPS. equities analysts forecast that Zimmer Biomet Holdings Inc will post 7.67 EPS for the current fiscal year.
Several equities analysts recently issued reports on the company. Argus lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Friday, June 22nd. Piper Jaffray Companies increased their target price on Zimmer Biomet from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Monday, July 30th. Zacks Investment Research lowered Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Monday, July 2nd. ValuEngine raised Zimmer Biomet from a “sell” rating to a “hold” rating in a research note on Wednesday, July 25th. Finally, Jefferies Financial Group increased their target price on Zimmer Biomet to $145.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $135.10.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Featured Article: Trading Strategy Methods and Types
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.